- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01837927
Efficacy of NVA237 (50 μg o.d) Using Tiotropium (5μg μg o.d) as Active Control in COPD Patients.
August 19, 2016 updated by: Novartis Pharmaceuticals
A 52-week Treatment, Multi-center, Randomized, Open Label, Parallel Group Study to Assess the Efficacy of NVA237 (50 μg o.d.) Using Tiotropium (5 μg o.d.) as an Active Control in Brazilian Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease.
This study will assess the Efficacy of NVA237 (50 μg o.d) using tiotropium (5μg μg o.d) as active control in COPD patients.
Study Overview
Status
Withdrawn
Conditions
Intervention / Treatment
Detailed Description
A 52-week treatment, multicenter, randomized, open-label, parallel-group study to assess the efficacy of NVA237 (50μg once daily) using Tiotropium (5μg once daily) as an active control in Brazilian patients with moderate to severe Chronic Obstructive Pulmonary Disease.
Study Type
Interventional
Phase
- Phase 3
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
40 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion:
- Men and women aged 40 years or over.
- History of current or former smoking of at least 10 pack-years
- Cooperative outpatients, with a COPD diagnosis established by the measurement of FEV1/FVC < 0.7 post-bronchodilation in basal spirometry (without use of medication or post-washout). Moderate to severe stage patients will be included, with post-bronchodilator FEV1 between 30 and 80% of the normal value according to GOLD 2011 since the inclusion criteria in this trial will be based on spirometry results.
Exclusion:
- Pregnant women or nursing mothers
History of asthma at visit 1 indicated by, but not limited to:
- Onset of respiratory symptoms suggestive of asthma (such as coughing, wheezing, shortness of breath) before the age of 40.
- History of diagnosed asthma
- History of respiratory tract infection within six weeks prior to Visit 1.
- History of hospitalization or emergency care for a COPD exacerbation in the 3 months prior to Visit 1.
- Subjects who require use of home oxygen therapy.
- Patients in the active phase of an assisted pulmonary rehabilitation program and patients who completed the rehabilitation program within 18 months from Visit 1 or 2 of the protocol.17,20
- Patients with known history and diagnosis of alpha-1 antitrypsin deficiency.
- Patients with concomitant lung disease, e.g.: tuberculosis (unless confirmed by radiography as inactive) or clinically significant bronchiectasis.
- Patients who in the investigator's judgment have an abnormality or significant medical condition such as: unstable ischemic heart disease, left ventricular failure, history of myocardial infarction, arrhythmia (except chronic stable atrial fibrillation), history of malignancy of any system (including lung cancer) treated or not within the last 5 years, glaucoma, prostatic hyperplasia, moderate to severe renal impairment, urinary retention, any other condition that might compromise patient safety or compliance, interfere with the evaluations, or prevent the termination of their participation in the study.
- Patients with contraindications to tiotropium or ipratropium treatment or who have experienced undesirable reactions with inhaled anticholinergic agents or patients with a history of an undesirable reaction with sympathomimetic amines or inhaled medication with any of those components, or a history of hypersensitivity to any of the study medications, including rescue medication, or similar classes of medication.
- Patients using tiotropium, long-acting anticholinergics, short-acting anticholinergics, fixed combinations of inhaled beta agonists and inhaled corticosteroids, theophylline. In these cases, the patient is allowed, after agreeing to participate in the study, to enter a washout period from Visit
- Patients using inhaled steroids, alone or as an exchange in a fixed combination at equivalent doses, unless on a stable treatment for at least 1 month prior to randomization
- Patients using nonselective beta-blockers.
- Patients using cromoglycate, nedocromil, ketotifen and leukotriene antagonists unless on stable treatment for at least 1 month prior to randomization .
- Patients who used oral prednisone (or equivalent) over a long period, defined as ≥ 10 mg/day for at least 1 month prior to Visit 1
- Patients who used intramuscular depot corticosteroids within 30 days from Visit 1.
- Patients with a history of long QT Syndrome or with prolonged QTc (> 450 ms) measured at Visit 1 (Fridericia Method).
- Patients who, in the opinion of the investigator, have clinically significant abnormalities on ECG. These patients should not be re-screened.
- Other exclusion criteria may apply
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: NVA237
NVA237 inhaled via the Breezhaler® device once daily
|
Once daily for 52 weeks
|
Active Comparator: Tiotropium
Tiotropium 5μg inhaled via the Respimat® device once daily
|
Once daily for 52 weeks
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change From Baseline in Forced Expiratory Volume in 1 Second (FEV1)
Time Frame: Baseline and 12 weeks after treatment.
|
Forced expiratory volume in 1 second (FEV1) is the amount of air that can be exhaled in one second.
FEV1 will be measured by spirometry.
A positive change from baseline in FEV1 indicates improvement in lung function.
|
Baseline and 12 weeks after treatment.
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Forced Expiratory Volume in 1 Second (FEV1) at day 1
Time Frame: 30 and 60 minutes post-dose on the first day of study treatment.
|
Forced expiratory volume in 1 second (FEV1) is the amount of air that can be exhaled in one second.
FEV1 will be measured by spirometry.
A positive change from baseline in FEV1 indicates improvement in lung function.
|
30 and 60 minutes post-dose on the first day of study treatment.
|
Forced Expiratory Volume in 1 Second (FEV1) at day 7 and weeks 12, 24 and 52
Time Frame: 30 and 60 minutes post-dose on the 7th day of study treatment and at weeks 12, 24 and 52
|
Forced expiratory volume in 1 second (FEV1) is the amount of air that can be exhaled in one second.
FEV1 will be measured by spirometry.
A positive change from baseline in FEV1 indicates improvement in lung function.
|
30 and 60 minutes post-dose on the 7th day of study treatment and at weeks 12, 24 and 52
|
Forced Expiratory Volume in 1 Second (FEV1) at weeks 24 and 52
Time Frame: pre-dose at weeks 24 and 52 of study treatment
|
Forced expiratory volume in 1 second (FEV1) is the amount of air that can be exhaled in one second.
FEV1 will be measured by spirometry.
A positive change from baseline in FEV1 indicates improvement in lung function.
|
pre-dose at weeks 24 and 52 of study treatment
|
Change From Baseline in Forced Vital Capacity (FVC)
Time Frame: Days 1 and 7, weeks 12, 24 and 52 of study treatment
|
Forced Vital Capacity (FVC) is the amount of air which can be forcibly exhaled from the lungs after taking the deepest breath possible.
FVC was assessed via spirometry.
A positive change from baseline in FVC indicates improvement in lung function.
|
Days 1 and 7, weeks 12, 24 and 52 of study treatment
|
FEV1 AUC 0-4h
Time Frame: 05, 30, 60 minutes and 4 hours post-dose at days 1, 7 and week 12
|
Forced Vital Capacity (FVC) is the amount of air which can be forcibly exhaled from the lungs after taking the deepest breath possible.
FVC was assessed via spirometry.
A positive change from baseline in FVC indicates improvement in lung function.
|
05, 30, 60 minutes and 4 hours post-dose at days 1, 7 and week 12
|
Safety and tolerance of NVA237
Time Frame: 52 weeks
|
All AEs and SAEs will be reported
|
52 weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
April 1, 2014
Primary Completion (Anticipated)
April 1, 2016
Study Completion (Anticipated)
April 1, 2016
Study Registration Dates
First Submitted
April 18, 2013
First Submitted That Met QC Criteria
April 18, 2013
First Posted (Estimate)
April 23, 2013
Study Record Updates
Last Update Posted (Estimate)
August 22, 2016
Last Update Submitted That Met QC Criteria
August 19, 2016
Last Verified
August 1, 2016
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Respiratory Tract Diseases
- Lung Diseases, Obstructive
- Lung Diseases
- Pulmonary Disease, Chronic Obstructive
- Physiological Effects of Drugs
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Parasympatholytics
- Autonomic Agents
- Peripheral Nervous System Agents
- Muscarinic Antagonists
- Cholinergic Antagonists
- Cholinergic Agents
- Adjuvants, Anesthesia
- Bronchodilator Agents
- Anti-Asthmatic Agents
- Respiratory System Agents
- Glycopyrrolate
- Tiotropium Bromide
Other Study ID Numbers
- CNVA237ABR01
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Pulmonary Disease, Chronic Obstructive
-
Spire, Inc.ResMedCompletedSevere Chronic Obstructive Pulmonary Disease | Moderate Chronic Obstructive Pulmonary DiseaseUnited States
-
Karaganda Medical UniversityCompletedChronic Obstructive Pulmonary Disease | Chronic Obstructive Pulmonary Disease Moderate | Chronic Obstructive Pulmonary Disease SevereKazakhstan
-
Randall DebattistaUniversity of Malta, Faculty of Health SciencesNot yet recruitingChronic Obstructive Pulmonary Disease Moderate | Acute Exacerbation of COPD | Chronic Obstructive Pulmonary Disease Severe
-
Cukurova UniversityCompletedAnesthesia | Chronic Obstructive Pulmonary Disease Moderate | Lungcancer | Chronic Obstructive Pulmonary Disease Severe | Chronic Obstructive Pulmonary Disease MildTurkey
-
National Taipei University of Nursing and Health...TerminatedChronic Pulmonary Disease | Chronic Obstructive Pulmonary Disease Exacerbation | Chronic Obstructive Pulmonary Disease With ExacerbationTaiwan
-
Taipei Medical UniversityUnknownChronic Obstructive Pulmonary Disease Severe | Chronic Obstructive Pulmonary Disease End StageTaiwan
-
Kırıkkale UniversityRecruitingCOPD (Chronic Obstructive Pulmonary Disease)Turkey
-
Hopital FochAir Liquide SARecruitingChronic Obstructive Pulmonary Disease SevereFrance
-
Fundación para la Investigación del Hospital Clínico...Not yet recruitingCOPD, Chronic Obstructive Pulmonary DiseaseSpain
-
Canandaigua VA Medical CenterRecruitingChronic Obstructive Pulmonary Disease ModerateUnited States
Clinical Trials on NVA237
-
Novartis PharmaceuticalsCompletedChronic Obstructive Pulmonary DiseaseUnited States, Germany, Hungary, Belgium, Poland, Spain, Netherlands
-
NovartisCompletedChronic Obstructive Pulmonary Disease (COPD)United States, Spain, Turkey, France, Netherlands, Germany
-
Novartis PharmaceuticalsWithdrawnChronic Obstructive Pulmonary Disease
-
Novartis PharmaceuticalsCompletedChronic Obstructive Pulmonary Disease (COPD)Greece, Belgium, Bulgaria, Turkey, Hungary, Slovakia, Spain, United Kingdom, Russian Federation, Ireland
-
Novartis PharmaceuticalsCompletedRenal ImpairmentRussian Federation
-
NovartisCompletedChronic Obstructive Pulmonary Disease (COPD)Germany, Denmark
-
Novartis PharmaceuticalsWithdrawn
-
Novartis PharmaceuticalsCompletedChronic Obstructive Pulmonary Disease (COPD)China, Philippines, Korea, Republic of, India
-
Novartis PharmaceuticalsCompleted
-
Novartis PharmaceuticalsCompletedChronic Obstructive Pulmonary DiseaseAustralia, New Zealand